Why walking further and faster could cut your risk of heart attack and stroke
Analysis of more than 36,000 people with high blood pressure revealed walking more reduces the risk of major problems in the heart and blood vessels.
The study published in the European Journal of Preventative Cardiology found that compared to a daily step count of 2,300 steps, every extra 1,000 steps was linked to a 17 per cent reduction in the risk of cardiovascular problems.
This was the case up to a step count of 10,000 – walking more than this was associated with a lower risk of stroke.
It's estimated that just over a quarter adults in the UK, around 14.4 million people, have high blood pressure, according to the British Heart Foundation.
It increases the risk of heart disease, heart attacks, strokes and heart failure, according to the NHS.
However, study authors say until now it has been unclear how much people with high blood pressure need to increase their physical activity to see a reduction in these risks.
Professor Emmanuel Stamatakis, at the University of Sydney, Australia, who supervised the study, said: 'We found that, if you live with high blood pressure, the more you walk with greater intensity, the lower your risk for future serious cardiovascular events.
'These findings support the message that any amount of physical activity is beneficial, even below the widely recommended daily target of 10,000 steps.'
Researchers analysed data from 32,192 people with high blood pressure who were part of the UK Biobank study – a cohort study of 500,000 people that collected data on diet, lifestyle, biomarkers, and health.
As part of the study these participants agreed to wear an accelerometer on their wrist for seven consecutive days to measure how far and how fast they walked.
The participants were followed up for eight years and during this time there were 1,935 cases of heart problems of stroke.
After analysing this data researchers discovered for every 1,000 steps a day there was a 17 per cent reduction in overall risk, 22 per cent reduction in heart failure, 9 per cent reduction in risk of heart attack, and 24 per cent reduction in risk of stroke.
Researchers also tracked how fast participants walked a day and recorded their fastest 30 minutes at an average of 80 steps a minute which was associated with a 30 per cent reduced risk of heart problems.
However, it's not just people with high blood pressure that could benefit. Researchers also found similar results when they looked at 37,350 people without high blood pressure.
Every 1,000-step increase in daily step count led to an average lower risk of overall heart problems (20.2 per cent), heart failure (23.2 per cent), myocardial infarctions (17.9 per cent) and stroke (24.6 per cent).
Professor Stamatakis said: 'Clinicians should promote physical activity as standard care, especially in patients with high blood pressure. Our results can inform new, tailored public health recommendations for these patients.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
16 minutes ago
- The Independent
The exercise hack that could cut your heart attack risk by a fifth
A study has revealed that increasing walking distance and speed can significantly lower the risk of heart attacks and strokes, even without reaching the recommended 10,000 steps daily. Published in the European Journal of Preventative Cardiology, the research analysed data from 32,192 people with high blood pressure from the UK Biobank study. The findings indicate that each additional 1,000 steps taken daily was linked to a 17 per cent reduction in the risk of cardiovascular problems. Professor Emmanuel Stamatakis, who supervised the study, emphasised that any amount of physical activity is beneficial, even below the widely recommended daily step target. While primarily focusing on people with high blood pressure, the study also found similar cardiovascular benefits for individuals without the condition. Why walking further and faster could cut your risk of heart attack and stroke
The Independent
16 minutes ago
- The Independent
High demand expected for new daily weight loss pill
A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially offering people with obesity a new and convenient alternative to jabs. Pharmaceutical company Eli Lilly said it expects substantial demand when the new pill is launched. Lilly said it will seek approval by international regulators as it published the results of a large study into orforglipron. The new pill is a GLP-1 agonist, a type of medication which helps lower blood sugar levels, slows the digestion of food and can reduce appetite. The manufacturer also makes Mounjaro, dubbed the King Kong of weight loss jabs. Weight loss jabs have been hailed as transformative by health leaders. But injections come with additional work for over-stretched health services so tablet forms of medication, which are expected to be cheaper and easier to use, may offer a new hope for the millions of people looking to lose weight. The new study data on orforglipron showed that people taking the drug lost an average of 12.3 kilograms while taking the drug for 72 weeks compared with those not taking the drug. Three in five (60%) of people taking the highest dose of orforglipron lost at least 10% of their body weight, while 40% lost at least 15% of their body weight, according to the study, which is to be presented to the European Association for the Study of Diabetes (EASD) Annual Meeting 2025. In addition to weight loss the people in the study also showed other health benefits, including improvements in cholesterol, blood pressure and heart disease risk. Experts highlighted how the tablet did not appear to yield the same benefits as some weight loss jabs, but said they will be more 'tolerable' for many patients. Lilly said the safety profile of the tablet is similar to other GLP-1 drugs, with gastrointestinal issues the most commonly reported side effect. The pill was assessed in a study of 3,127 adults who were obese or overweight, with a weight-related medical problem and without diabetes. 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments,' said Lilly's Kenneth Custer. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, senior lecturer in physiology at Anglia Ruskin University, said: 'These early results on the effectiveness of orforglipron in promoting clinically significant weight loss are a positive step forward in the development of this class of drugs. 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'Nevertheless, that this medication is an oral form, rather than injectable, will likely be seen as more tolerable for many patients. 'The manufacturing costs are also anticipated to be significantly lower than injectable drugs, meaning these medications may be more equitable in their availability. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.' It comes as a separate study highlighted the potential other benefits of using GLP-1s, also known as glucagon-like peptide 1 receptor-agonists. They were initially developed as a treatment for people with type 2 diabetes and are now widely used to treat obesity and help people lose weight. The separate paper, from McGill University and the Lady Davis Institute for Medical Research at the Jewish General Hospital in Canada, examined the benefits of these drugs beyond weight loss by looking at trials which had assessed the drugs in other areas of medicine. Writing in the journal eClinicalMedicine, experts said GLP-1s may also play a role in improving liver disease; sleep apnoea; arthritis of the knee; polycystic ovary syndrome; Parkinson's disease; Alzheimer's disease and substance misuse. But they also highlighted potential safety issues linked to the drugs including potential issues with the pancreas and gall bladder. 'The therapeutic landscape for obesity and related metabolic conditions has evolved substantially with the emergence of GLP-1 RAs,' they wrote. 'These agents now play a central role not only in weight management and diabetes care but are also being investigated in a growing number of conditions, including cardiovascular, renal, hepatic, neurologic, and substance use disorders. 'As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centred treatment strategies.'
Daily Mirror
17 minutes ago
- Daily Mirror
Brits told to shut windows for the next four weeks due to 'toxic invader'
False Widow spiders are on the move and are expected to invade UK homes as mating season for the deadly breed begins. These eight-legged creatures are relatives of the lethal Black Widow Enormous spiders armed with wasp-like stings are gearing up to storm British households, forcing residents to take urgent precautions. False Widows are regarded as Britain's most toxic spider and can deliver an agonising bite - they're among just 12 UK spider species known to have attacked humans. These eight-legged creatures are relatives of the lethal Black Widow and are poised for their yearly mating ritual invasion of our homes. While their bite won't kill you, their poison can cause swelling and excruciating burns, potentially triggering fever. In other similar news, Brits are told to never put one banned item in garden bins as you could face punishment. Rid your home and garden of ants with natural 10-second method This dangerous species has now become firmly entrenched in properties throughout Britain, reports the Express. Top arachnologist Dr Tom Elwood reveals: "August is when male spiders become active". He continues: "They're searching for a mate and they'll wander through open windows, up walls, into bathtubs - anywhere they can." Dr Elwood explains it's not just open windows that lure spiders inside - it's the grime and rubbish accumulating on countless windowsills and frames. "Spiders are drawn to dust, insect remains and debris on window frames," he clarifies. "Webs cling better to rough or grimy surfaces. That's why cleaning your windows is just as important as keeping them shut." These arachnids are frequently spotted on floors, beside skirting boards and scaling walls. Delivering a chilling alert, Dr Elwood warns: "Spiders are already on the move. "You may not see them, but they're out there - climbing walls, slipping in through vents, and squeezing through the tiniest cracks. " Dr Elwood suggests keeping windows shut both day and night, stating that this isn't "paranoia - it's smart preparation". Here's how to keep False Widows at bay: Keep windows closed at all times Clean glass and frames every week Close any visible gaps or cracks Use vinegar sprays to avoid web-building Tidy corners and darker parts of the house where spiders hide "Do the right things now, and you won't be waking up to spiders crawling across your bedroom floor," he concludes. As they're most actively and frequently seen from July to November, it's important to take immediate action to prevent them from marking territory in your home. So, if you're afraid of spiders, don't worry - by doing following these simple instructions, you'll be avoiding False Widow spiders and any other insects and keep them far away from you.
